Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674723 | 0.86 | CHRNA7 (0.38) | CHRNA7GAATSHRCASP1 | |
| SCHEMBL28137945 | 0.83 | CHRNA7 (0.46) | CHRNA7GAATSHRCASP1 | |
| SCHEMBL1114215 | 0.79 | CHRNA7 (0.48) | CHRNA7GAATSHRCASP1 | |
| SCHEMBL28137322 | 0.74 | CHRNA7 (0.39) | CHRNA7GAATSHRCASP1 | |
| SCHEMBL1114359 | 0.74 | HPGD (0.59) | GAATSHR | |
| SCHEMBL8662784 | 0.74 | CHRNA7 (0.44) | CHRNA7GAATSHRCASP1 | |
| SCHEMBL14434130 | 0.74 | HPGD (0.52) | CHRNA7TSHR | |
| SCHEMBL14861099 | 0.74 | KDM4E (0.40) | GAA | |
| SCHEMBL14434133 | 0.74 | CHRNA7 (0.44) | CHRNA7GAATSHRCASP1 | |
| SCHEMBL19331822 | 0.74 | TSHR (0.39) | CHRNA7GAATSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187924-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TUMOR NECROSIS FACTOR-ALPHA-MEDIATED DISEASES | DARWIN DISCOVERY, LTD. (GB) | 2001-02-13 | — | — | US | claimed |
| WO-2017156177-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| CN-101687864-A | 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors | ASTRAZENECA AB | 2010-03-31 | — | — | CN | disclosed |
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | TEIJIN, LIMITED (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1030836-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LTD (GB) | 2003-01-29 | — | — | EP | disclosed |
| EP-1030836-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024399-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | CHRNA7 3451/4885GAA 2724/4885TSHR 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.